上皮癌-话题@MedSci

#上皮癌#

151篇内容 | 1384人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1539425, encodeId=0834153942524, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=J Clin Oncol：化疗后采用鲁卡帕尼维持治疗DNA修复缺陷阳性转移性尿路上皮癌, objectType=article, longId=736046, objectId=9162e3604691, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9162e3604691, replyNumber=0, likeNumber=0, createdTime=2022-08-18, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9162e3604691, moduleTitle=J Clin Oncol：化疗后采用鲁卡帕尼维持治疗DNA修复缺陷阳性转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9162e3604691)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539424, encodeId=15a71539424bd, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=北京基因组所等鉴定出尿路上皮癌中具有预后分层的DNA甲基化亚型, objectType=article, longId=735769, objectId=cf8fe35769ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf8fe35769ab, replyNumber=0, likeNumber=52, createdTime=2022-08-14, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf8fe35769ab, moduleTitle=北京基因组所等鉴定出尿路上皮癌中具有预后分层的DNA甲基化亚型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf8fe35769ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539423, encodeId=7c84153942384, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, objectType=article, longId=730487, objectId=eb89e30487a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb89e30487a4, replyNumber=0, likeNumber=27, createdTime=2022-06-27, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb89e30487a4, moduleTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb89e30487a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539422, encodeId=f731153942221, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=J Clin Oncol：杜瓦鲁单抗联合奥拉帕利治疗初治的转移性尿路上皮癌的疗效和安全性, objectType=article, longId=730446, objectId=7c9fe304466b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c9fe304466b, replyNumber=0, likeNumber=52, createdTime=2022-06-26, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c9fe304466b, moduleTitle=J Clin Oncol：杜瓦鲁单抗联合奥拉帕利治疗初治的转移性尿路上皮癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c9fe304466b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539421, encodeId=a1db15394213c, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=ASCO2022：除癌症分级与分期外，这些因素也会影响上尿路上皮癌患者的预后, objectType=article, longId=728376, objectId=7668e283761c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7668e283761c, replyNumber=0, likeNumber=34, createdTime=2022-06-02, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7668e283761c, moduleTitle=ASCO2022：除癌症分级与分期外，这些因素也会影响上尿路上皮癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7668e283761c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539420, encodeId=f35e1539420d8, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=ASCO2022：纳武利尤单抗能显著增加高危肌层浸润性尿路上皮癌患者无病生存时间, objectType=article, longId=728372, objectId=b310e283729d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b310e283729d, replyNumber=0, likeNumber=31, createdTime=2022-06-02, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b310e283729d, moduleTitle=ASCO2022：纳武利尤单抗能显著增加高危肌层浸润性尿路上皮癌患者无病生存时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b310e283729d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539419, encodeId=dd4c153941928, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=J Immunother Cancer：卡瑞利珠单抗联合法米替尼治疗铂类进展的晚期或转移性尿路上皮癌的疗效和安全性, objectType=article, longId=726649, objectId=3c23e2664918, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c23e2664918, replyNumber=0, likeNumber=33, createdTime=2022-05-13, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c23e2664918, moduleTitle=J Immunother Cancer：卡瑞利珠单抗联合法米替尼治疗铂类进展的晚期或转移性尿路上皮癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c23e2664918)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539418, encodeId=10b915394185d, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Ther Adv Med Onco：骨转移对尿路上皮癌患者预后的预测意义, objectType=article, longId=726368, objectId=ed4be2636815, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed4be2636815, replyNumber=0, likeNumber=32, createdTime=2022-05-09, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed4be2636815, moduleTitle=Ther Adv Med Onco：骨转移对尿路上皮癌患者预后的预测意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed4be2636815)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539417, encodeId=f176153941e65, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌, objectType=article, longId=724545, objectId=4673e2454541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4673e2454541, replyNumber=0, likeNumber=40, createdTime=2022-04-20, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4673e2454541, moduleTitle=Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4673e2454541)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539416, encodeId=ae4f153941631, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=NICE推荐Bavncio (avelumab)治疗局部晚期转移性尿路上皮癌 (UC), objectType=article, longId=724472, objectId=bbc0e244722a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbc0e244722a, replyNumber=0, likeNumber=47, createdTime=2022-04-19, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbc0e244722a, moduleTitle=NICE推荐Bavncio (avelumab)治疗局部晚期转移性尿路上皮癌 (UC), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbc0e244722a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539415, encodeId=cdb1153941538, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=J Clin Oncol：晚期尿路上皮癌患者采用纳武单抗定制疗法的临床疗效, objectType=article, longId=300810, objectId=d19e300810ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d19e300810ee, replyNumber=0, likeNumber=33, createdTime=2022-03-16, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d19e300810ee, moduleTitle=J Clin Oncol：晚期尿路上皮癌患者采用纳武单抗定制疗法的临床疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d19e300810ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539414, encodeId=2bbc15394145f, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Eur Urol：恩福单抗维多汀治疗局部晚期或转移性尿路上皮癌的疗效如何？, objectType=article, longId=299913, objectId=686d29991338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=686d29991338, replyNumber=0, likeNumber=36, createdTime=2022-03-03, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=686d29991338, moduleTitle=Eur Urol：恩福单抗维多汀治疗局部晚期或转移性尿路上皮癌的疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=686d29991338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539413, encodeId=09aa153941326, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=CHMP支持Opdivo治疗食管、尿路上皮癌, objectType=article, longId=299738, objectId=b3b3299e38c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3b3299e38c5, replyNumber=0, likeNumber=25, createdTime=2022-03-01, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3b3299e38c5, moduleTitle=CHMP支持Opdivo治疗食管、尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3b3299e38c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539412, encodeId=45a71539412f2, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Cancer Treat Rev：免疫 pk 化疗，一线治疗晚期尿路上皮癌, objectType=article, longId=299225, objectId=42b329922588, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42b329922588, replyNumber=0, likeNumber=37, createdTime=2022-02-21, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42b329922588, moduleTitle=Cancer Treat Rev：免疫 pk 化疗，一线治疗晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42b329922588)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539411, encodeId=ea5d1539411e8, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Clin Cancer Res：采用卡博替尼联合纳武单抗治疗PCI难治性转移性尿路上皮癌, objectType=article, longId=295762, objectId=3cdc295e62fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cdc295e62fa, replyNumber=0, likeNumber=42, createdTime=2022-02-17, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cdc295e62fa, moduleTitle=Clin Cancer Res：采用卡博替尼联合纳武单抗治疗PCI难治性转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cdc295e62fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539410, encodeId=64e515394107f, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=European Radiology：FROC模型和双参数VI-RADS对膀胱尿路上皮癌分期和分级的评价, objectType=article, longId=293825, objectId=89ce2938257f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89ce2938257f, replyNumber=0, likeNumber=45, createdTime=2022-01-13, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89ce2938257f, moduleTitle=European Radiology：FROC模型和双参数VI-RADS对膀胱尿路上皮癌分期和分级的评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89ce2938257f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539409, encodeId=fd1c1539409cd, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Eur Urol：不同分子亚型的尿路上皮癌对新辅助化疗的差异反应分析, objectType=article, longId=221754, objectId=a389221e54ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a389221e54ed, replyNumber=0, likeNumber=43, createdTime=2021-12-10, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a389221e54ed, moduleTitle=Eur Urol：不同分子亚型的尿路上皮癌对新辅助化疗的差异反应分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a389221e54ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539408, encodeId=fea4153940813, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=CCR：君实特瑞普利单抗对尿路上皮癌具有持久的临床应答（POLARIS-03研究）, objectType=article, longId=220472, objectId=39872204e2fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39872204e2fd, replyNumber=0, likeNumber=38, createdTime=2021-11-18, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39872204e2fd, moduleTitle=CCR：君实特瑞普利单抗对尿路上皮癌具有持久的临床应答（POLARIS-03研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39872204e2fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539407, encodeId=d6c0153940e61, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=君实生物特瑞普利单抗治疗尿路上皮癌POLARIS-03研究获《临床癌症研究》杂志在线发表, objectType=article, longId=220465, objectId=a903220465fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a903220465fc, replyNumber=0, likeNumber=25, createdTime=2021-11-18, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a903220465fc, moduleTitle=君实生物特瑞普利单抗治疗尿路上皮癌POLARIS-03研究获《临床癌症研究》杂志在线发表, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a903220465fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539406, encodeId=d4c01539406be, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Clin Cancer Res：托瑞帕利单抗二线治疗转移性尿路上皮癌的疗效、安全性和生物标志物, objectType=article, longId=220114, objectId=de3b22011460, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de3b22011460, replyNumber=0, likeNumber=39, createdTime=2021-11-12, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de3b22011460, moduleTitle=Clin Cancer Res：托瑞帕利单抗二线治疗转移性尿路上皮癌的疗效、安全性和生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de3b22011460)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

上皮癌

2020-05-29

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

J Clin Oncol：化疗后采用鲁卡帕尼维持治疗DNA修复缺陷阳性转移性尿路上皮癌

2022-08-18

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

北京基因组所等鉴定出尿路上皮癌中具有预后分层的DNA甲基化亚型

2022-08-14

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？

2022-06-27

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

J Clin Oncol：杜瓦鲁单抗联合奥拉帕利治疗初治的转移性尿路上皮癌的疗效和安全性

2022-06-26

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

ASCO2022：除癌症分级与分期外，这些因素也会影响上尿路上皮癌患者的预后

2022-06-02

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

ASCO2022：纳武利尤单抗能显著增加高危肌层浸润性尿路上皮癌患者无病生存时间

2022-06-02

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

J Immunother Cancer：卡瑞利珠单抗联合法米替尼治疗铂类进展的晚期或转移性尿路上皮癌的疗效和安全性

2022-05-13

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Ther Adv Med Onco：骨转移对尿路上皮癌患者预后的预测意义

2022-05-09

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌

2022-04-20

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

NICE推荐Bavncio (avelumab)治疗局部晚期转移性尿路上皮癌 (UC)

2022-04-19

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

J Clin Oncol：晚期尿路上皮癌患者采用纳武单抗定制疗法的临床疗效

2022-03-16

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Eur Urol：恩福单抗维多汀治疗局部晚期或转移性尿路上皮癌的疗效如何？

2022-03-03

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

CHMP支持Opdivo治疗食管、尿路上皮癌

2022-03-01

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Cancer Treat Rev：免疫 pk 化疗，一线治疗晚期尿路上皮癌

2022-02-21

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Clin Cancer Res：采用卡博替尼联合纳武单抗治疗PCI难治性转移性尿路上皮癌

2022-02-17

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

European Radiology：FROC模型和双参数VI-RADS对膀胱尿路上皮癌分期和分级的评价

2022-01-13

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Eur Urol：不同分子亚型的尿路上皮癌对新辅助化疗的差异反应分析

2021-12-10

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

CCR：君实特瑞普利单抗对尿路上皮癌具有持久的临床应答（POLARIS-03研究）

2021-11-18

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

君实生物特瑞普利单抗治疗尿路上皮癌POLARIS-03研究获《临床癌症研究》杂志在线发表

2021-11-18

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Clin Cancer Res：托瑞帕利单抗二线治疗转移性尿路上皮癌的疗效、安全性和生物标志物

2021-11-12

科室
- - 订阅+
  - 更多科室
工具
服务